Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone Thorough QT/QTc Study
NCT01860703Phase 4Completed
- Sponsor
- ApoPharma Inc.
- Start
- Nov 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of deferiprone in Transfusional Iron Overload (TIO) (4 arms), sponsored by ApoPharma Inc. Primary endpoints: Maximum Difference in Change From Baseline in ddQTcF at 24 hours, Maximum Postdose QT/QTc Interval at 24 hours and 1 more. Started Nov 2012; status: completed.
02
Drugs
deferiprone
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT01860703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860703.